Sun Pharma-Ranbaxy deal in CCI crosshairs
Mint
2018-02-16
Views 1
SunPharma acquired Ranbaxy for $3.2 billion, but now faces a major hurdle with the Competition Commission of India. The joining of two of India's largest pharma companies could result in significant market domination, greatly affecting the prices of essential, life-saving drugs in the domestic market.
Report form
RELATED VIDEOS
